- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2020 MJH Life Sciences and Rheumatology Network. All rights reserved.
10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
A study published in the April 25 issue of Arthritis Care and Research, shows that patients with PsA have a 55% increase in the risk of incident cardiovascular events. The overall risk of cardiovascular disease is 43% greater than that of the general population. By comparison, PsA patients face a 31% increased risk of congestive heart failure, 38% increased risk of incident cerebrovascular events and 57% increased risk of developing myocardial infarction. “Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies.” Ari Polachek, M.D., Zahi Touma, M.D., Ph.D., et. al. Arthritis Care and Research. April 25, 2016. DOI: 10.1002/acr.22926.Â
“Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies.” Ari Polachek, M.D., Zahi Touma, M.D., Ph.D., et. al. Arthritis Care and Research. April 25, 2016. DOI: 10.1002/acr.22926. Framingham Heart Study, Cardiovascular Disease (10-year risk)
“Atherosclerosis in psoriatic disease: latest evidence and clinical implications.” Lihi Eder and Dafna D. Gladman, Therapeutic Advances in Musculoskeletal Disease. October 2015. DOI: 10.1177/1759720X15591801
“Atherosclerosis in psoriatic disease: latest evidence and clinical implications.” Lihi Eder and Dafna D. Gladman, Therapeutic Advances in Musculoskeletal Disease. October 2015. DOI: 10.1177/1759720X15591801
“Self-reported depression in psoriasis is associated with subclinical vascular diseases.” Aberra TM, Joshi AA, et al. Atherosclerosis. May 27, 2016. DOI: 10.1016/j.atherosclerosis.2016.05.043.
"Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis." Egeberg A, Bruun LE, et. al. Journal of the American Academy of Dermatology. June 6, 2016. DOI: 10.1016/j.jaad.2016.02.1227
“Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions.” Haroon M, Rafiq Chaudhry AB, Fitzgerald O. Journal of Rheumatology. February 2016. DOI: 10.3899/jrheum.150757.
"The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients." Ku SH, Kwon W.J. et. al. Annals of Dermatology. May 25, 2016. DOI: 10.5021/ad.2016.28.3.360.
"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis." The Lancet. Jan 9, 2010. DOI: 10.1016/S0140-6736(09)61717-7
“Managing Cardiovascular Disease in Patients with Rheumatoid Arthritis?” Rheumatology Nurse Practice Volume 2, Issue 1."Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study," Hyon K Choi, MD, Miguel A Hernán, MD, et. al. The Lancet. April 6, 2002. DOI: http://dx.doi.org/10.1016/S0140-6736(02)08213-2
"Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis." Hjuler KF, Bøttcher M, et. al. JAMA Dermatology. July 7, 2016. DOI: 10.1001/jamadermatol.2016.1984. “Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.” Piaserico S, Osto E, et al. Atherosclerosis. May 21, 2016. DOI: 10.1016/j.atherosclerosis.2016.05.036.